Download PDF
Drug Res (Stuttg) 2019; 69(01): 53-60
DOI: 10.1055/a-0651-7939
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Butanol Fraction of Olax Subscorpioidea Produces Antidepressant Effect: Evidence for the Involvement of Monoaminergic Neurotransmission

Adebayo O. Adeoluwa
1   Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medicine and Health Sciences, Afe Babalola University Ado Ekiti, Ekiti State, Nigeria
,
Oladele A. Aderibigbe
2   Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Oyo State Nigeria
,
Isaiah O. Agboola
3   Department of Pharmacognosy and Herbal Medicine, Faculty of Pharmacy, Niger Delta University, Wilberforce Island Bayelsa State, Nigeria
,
Toyin E. Olonode
1   Department of Pharmacology and Therapeutics, Faculty of Basic Clinical Sciences, College of Medicine and Health Sciences, Afe Babalola University Ado Ekiti, Ekiti State, Nigeria
,
Benneth Ben-Azu
2   Department of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Oyo State Nigeria
› Author Affiliations
Further Information

Publication History

received 26 December 2017

accepted 01 June 2018

Publication Date:
02 August 2018 (online)

Also available at
    Permissions and Reprints

Abstract

This study sought to investigate involvement of monoaminergic mechanism in the antidepressant action of butanol fraction (BF) of Olax subscorpioidea in rodents and the bioactive principles present. Butanol fraction was evaluated for antidepressant-like effect in the tail suspension, forced swimming and open field tests. All animals were treated with BF (5, 10 & 20 mg/kg) thirty minutes prior to the tests. On the other hand, monoaminergic neurotransmission involvement was probed by pre-treating animals with yohimbine hydrochloride (1 mg/kg, α2 antagonist), prazosin (62.5 µg/kg, α1 antagonist), propranolol (2 mg/kg, non-selective β antagonist), sulpiride (50 mg/kg, D2 receptor blocker), haloperidol (0.2 mg/kg, non-selective D receptor blocker), metergoline (4 mg/kg, i.p., a 5HT-receptor blocker) and PCPA (100 mg/kg, i.p., inhibitor of tryptophan hydroxylase), fifteen minute before treatment with BF (10 mg/kg). Identification of the major bioactive constituents was done by HPLC. The findings show that BF (5 & 10 mg/kg) significantly decreased immobility in despair tests of depression without effect on locomotor activity. The data also shows that anti-immobility effect of BF (10 mg/kg) in the TST was reversed by prazosin, yohimbine, haloperidol, sulpiride, metagoline and PCPA but not with propranolol. Bioactive principles present are caffeic acid, rutin, morin and quercetin. In conclusion, our findings show that BF produces antidepressant-like effect, which may be dependent on its interaction with the monoaminergic system.

Key words

Olax subscorpioidea - Olacecae - monoaminergic transmission - depression
 

  • References

  • 1 WHO. Mental health: Facing the challenges, building solutions. Report from the WHO European Ministerial Conference. Copenhagen, Denmark: WHO Regional Office for Europe; 2005
    Google Scholar
  • 2 Elhwuegi AS. Central monoamines and their role in major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2004; 28: 435-451
    CrossrefPubMedGoogle Scholar
  • 3 Papakostas GI. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacology 2006; 16: 391-402
    CrossrefPubMedGoogle Scholar
  • 4 Ibrahim JA, Muazzam I, Jegede IA. et al. Ethno-medicinal plants and methods used by Gwandara tribe of Sabo Wuse in Niger state, Nigeria, to treat mental illness. African Journal of Traditional, Complementary and Alternative Medicines 2007; 4: 211-218
    PubMedGoogle Scholar
  • 5 Victoria UC, Micheal UC, Johnny MU. Evaluation of the antiulcer activity of Olax subscorpioidea Oliv. Roots in rats. Asian Pacific Journal of Tropical Medicine 2010; 3: 13-16
    CrossrefPubMedGoogle Scholar
  • 6 Bouquet A.Féticheurs et médecines traditionnelles du Congo (Brazzaville). Mém. O.R.S.T.O.M., http://www.docstoc.com/docs/41737230/Ficheurs-et-mecines-tradition 1969; 36: 282
    PubMed
  • 7 Sonibare MA, Gbile ZO. Ethnobotanical survey of anti-asthmatic plants in south western Nigeria. Afr. J. Trad. CAM 5 2008; 4: 340-345
    PubMedGoogle Scholar
  • 8 Mike OS, Amusa NA, Raji-Esan SO. et al. Ethnobotanical Survey of Anti-Cancer Plants in Ogun State, Nigeria. Annals of Biological Research 2010; 1: 261-273
    PubMedGoogle Scholar
  • 9 Soladoye MO, Amusa NA, Raji-Esan SO. et al. Ethnobotanical survey of anti-cancer plants in Ogun state, Nigeria. Ann Biol Res 2010; 1: 261-273
    PubMedGoogle Scholar
  • 10 Adjanohoun EV, Adjakidje MRA, Ahyi K et al. Contribution aux études ethnobotaniques et floristiques au Togo. Agence de coopération culturelle et technique, (A.C.C.T.), Paris, 671 p., From the data bank PHARMEL 2 (ref. HP 10) 1986;
    PubMed
  • 11 Ayandele AA, Adebiyi AO. The phytochemical analysis and antimicrobial screening of extracts of Olax subscorpioidea. African Journal of Biotechnology 2007; 6: 868-870
    PubMedGoogle Scholar
  • 12 Adeoluwa OA, Aderibigbe AO, Olonode ET. Antinociceptive property of ethanol leaf extract of Olax subscorpioidea. Journal of Ethnopharmacology 2014; 156: 353-357
    CrossrefPubMedGoogle Scholar
  • 13 Ishola IO, Akinyede A, Lawal SW. et al. Antinociceptive and anti-inflammatory effects of Olax subscorpioidea Oliv. (Olacaceae) leaf extract in rodents: Possible mechanisms of antinociceptive action. West African Journal of Pharmacy 2015; 26: 99-112
    PubMedGoogle Scholar
  • 14 Adeoluwa OA, Aderibigbe AO, Bakre AG. Evaluation of antidepressant-like effect of Olax subscorpioidea Oliv. (Olacaceae) extract in mice. Drug Research 2015; 65: 306-311
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Adeoluwa OA, Aderibigbe AO, Agu AG. Pharmacological evaluation of central nervous system effects of ethanol leaf extract of Olax subscorpioidea in experimental animals. Drug Research 2016; 65: 1-7
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kazeem MI, Ayeleso OA, Mukwevho E. Olax subscorpioidea Oliv. Leaf alleviates postprandial hyperglycaemia by inhibition of alpha-amylase and alpha-glucosidase. International journal of Pharmacology 2015; 11: 484-489
    CrossrefPubMedGoogle Scholar
  • 17 Adegbite OS, Akinsaya YI, Kukoyi AJ. et al. Induction of rat hepatic mitochondrial membrane permeability transition pore opening by leaf extract of Olax subscorpioidea. Pharmacognosy Research 2015; 7: S63-S68
    CrossrefPubMedGoogle Scholar
  • 18 Porsolt RD. Behavioural Despair, in antidepressants: Neurochemical, behavioural and clinical perspectives. Eds. by Enna SJ, Malick JB, Richelson E. New York: Raven Press; 1981: 121-139
    Google Scholar
  • 19 Porsolt RD, Anton G, Blavet N. et al. Behavioral despair in rats. A new animal model sensitive to antidepressive treatments. Eur J Pharmacol. 1978; 47: 379-391
    CrossrefPubMedGoogle Scholar
  • 20 Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005; 29: 571- 625
    CrossrefPubMedGoogle Scholar
  • 21 Thierry B, Steru L, Simon P. et al. The tail suspension test: Ethical considerations. Psychopharmacology 1986; 90: 284-285
    PubMedGoogle Scholar
  • 22 Renard CE, Dailly E, David DJ. et al. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. Fundam Clin Pharmacology 2003; 17: 449 - 455
    PubMedGoogle Scholar
  • 23 Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509-522
    CrossrefPubMedGoogle Scholar
  • 24 Duman RS, Henninger GR, Nestler EJ. A molecular and cellular theory of depression. Archives of General Psychiatry 1997; 54: 597- 606
    CrossrefPubMedGoogle Scholar
  • 25 Wong MA, Licinio J. Research and treatments approaches to depression. Nature neuroscience 2001; 2: 343-351
    CrossrefPubMedGoogle Scholar
  • 26 Wang YM, Xu F, Gainetdinov RR. et al. Genetic approaches to studying norepinephrine function: Knockout of the mouse norepinephrine transporter gene. Biol Psychiatry 1999; 46: 1124-1130
    CrossrefPubMedGoogle Scholar
  • 27 Brunello N, Blier P, Judd LL. et al. Noradrenaline in mood and anxiety disorders: Basic and clinical studies. International clinical psychopharmacology 2003; 18: 191-202
    CrossrefPubMedGoogle Scholar
  • 28 Dziedzicka-Wasylewska M, Faron-Górecka A, Kuśmider M. et al. Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology 2006; 31: 2424-2432
    CrossrefPubMedGoogle Scholar
  • 29 Danysz W, Kostowski W, Kozak W. et al. On the role of noradrenergic neurotransmission in the action of desipramine and amitriptyline in animal models of depression. Pol. J. Pharmacol. Pharm. 1998; 38: 285-298
    PubMedGoogle Scholar
  • 30 Masuda Y, Ohnuma S, Sugiyama T. α 2-adrenoceptor activity induces the antidepressant-like glycolipid in mouse forced swimming. Methods Find Exp Clin Pharmacol. 2001; 23: 19 -21
    CrossrefPubMedGoogle Scholar
  • 31 Stone EA, Grunewald GL, Lin Y. et al. Role of epinephrine stimulation of CNS α 1-adrenoceptors in motor activity in mice. Synapse 2003; 4 9: 67-76
    PubMedGoogle Scholar
  • 32 Flugge G, Van Kampen M, Meyer H. et al. α2A and α2C-adrenoceptor regulation in the brain: α2A changes persist after chronic stress. European Journal of Neuroscience 2003; 17: 917-928
    CrossrefPubMedGoogle Scholar
  • 33 Ordway GA, Schenk J, Stockmeier CA. et al. Elevated agonist binding to α 2-adrenoceptors in the locus coeruleus in major depression. Biological psychiatry 2003; 53: 315-323
    CrossrefPubMedGoogle Scholar
  • 34 Kitada Y, Miyauchi T, Kanazawa Y. et al. Involvement of α- and β 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology 1983; 22: 1055- 1060
    CrossrefPubMedGoogle Scholar
  • 35 Millan MJ. The role of monoamines in the actions of established and “novel” antidepressant agents: A critical review. Eur J Pharmacol 2004; 500: 371-384
    CrossrefPubMedGoogle Scholar
  • 36 D'Aquila PS, Collu M, Gessa GL. et al. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000; 405: 365 -373
    CrossrefPubMedGoogle Scholar
  • 37 Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Dis 2005; 86: 37 - 45
    CrossrefPubMedGoogle Scholar
  • 38 Waehrens J, Gerlach J. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients. J Affect Disord 1981; 3: 193 -202
    CrossrefPubMedGoogle Scholar
  • 39 Dailly E, Chenu F, Renard CE. et al. Dopamine, depression and antidepressants. Fundam Clin Pharmacol. 2004; 6: 601-607
    PubMedGoogle Scholar
  • 40 Yamada J, Sugimoto Y, Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 2004; 504: 207 - 211
    CrossrefPubMedGoogle Scholar
  • 41 Teste JF, Martin I, Rinjard P. Electrotherapy in mice: Dopaminergic and noradrenergic effects in the Tail Suspension Test. Fundam Clin Pharmacol 1990; 4: 39-47
    CrossrefPubMedGoogle Scholar
  • 42 Ansorge MS, Hen R, Gingrich JA. Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol 2007; 53: 8-17
    PubMedGoogle Scholar
  • 43 Montgomery SA. Predicting response: noradrenaline reuptake inhibition. International Clinical Psychopharmacology 1999; 14: 21-26
    CrossrefPubMedGoogle Scholar
  • 44 Taylor S, Stein MB. The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Medical Hypotheses 2006; 66: 14-21
    CrossrefPubMedGoogle Scholar
  • 45 Kreiss DS, Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol. Exp Ther 1995; 274: 866 -876
    PubMedGoogle Scholar
  • 46 Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression?. Biological Psychiatry 2003; 53: 193 -203
    CrossrefPubMedGoogle Scholar
  • 47 Carvalho AF, Machado JR, Cavalcante JL. Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 2008; 22: 7-12
    PubMedGoogle Scholar
  • 48 Shelton RC, Tollefson GD, Tohen M. et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-134
    CrossrefPubMedGoogle Scholar
  • 49 Diaz SL, Doly S, Narboux-Neme N. et al. 5-HT2B receptors are required for serotonin-selective antidepressant actions. Mol Psychiatry 2012; 17: 154-163
    PubMedGoogle Scholar
  • 50 Cryan JF, Lucki I. Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine (2C) receptors. J Pharmacol Exp Ther 2000; 295: 1120-1126
    PubMedGoogle Scholar
  • 51 Cesana R, Ceci A, Ciprandi C. et al. Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. Journal of Pharmacy and Pharmacology 1993; 45: 473-475
    CrossrefPubMedGoogle Scholar
  • 52 O’Leary OF, Bechtholt AJ, Crowley JJ. et al. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology 2007; 192: 357-371
    CrossrefPubMedGoogle Scholar
  • 53 Page ME, Detke MJ, Dalvi A. et al. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 1999; 147: 162-167
    CrossrefPubMedGoogle Scholar
  • 54 An L, Zhang YZ, Yu NJ. et al. The total flavonoids extracted from Xiaobuxin-Tang up-regulate the decreased hippocampal neurogenesis and neurotrophic molecules expression in chronically stressed rats. Progress in NeuroPsychopharmacology and Biological Psychiatry 2008; 32: 1484-1490
    CrossrefPubMedGoogle Scholar
  • 55 Guan L-P, Liu B-Y. Antidepressant-like effects and mechanisms of flavonoids and related analogues. European Journal of Medicinal Chemistry 2016; 121: 47-57
    CrossrefPubMedGoogle Scholar
  • 56 Dixon Clarke SE, Ramsay RR. Dietary inhibitors of monoamine oxidase A. J Neural Transm 2011; 118: 1031-1041
    CrossrefPubMedGoogle Scholar
  • 57 Sakakibara H, Ishida K, Grundmann O. et al. Antidepressant effect of extracts from Ginkgo biloba leaves in behavioral models. Biol Pharm Bull 29: 1767-1770
    PubMedGoogle Scholar